×
About 1,105 results

ALLMedicine™ Posterior Uveitis Center

Research & Reviews  251 results

MULTICOLOR CONFOCAL SCANNING LASER OPHTHALMOSCOPE IMAGING IN POSTERIOR UVEITIS.
https://doi.org/10.1097/IAE.0000000000003444
Retina (Philadelphia, Pa.); Gupta K, Agarwal A et. al.

Jun 21st, 2022 - To study the utility of MultiColor confocal scanning laser ophthalmoscope imaging (MCI) in identifying the morphology of uveitic lesions compared with conventional color fundus photography (CFP) in patients with posterior uveitis. In this prospect...

Alezzandrini Syndrome
https://emedicine.medscape.com/article/1117255-overview

Jun 8th, 2022 - Practice Essentials In 1959, Casala and Alezzandrini [1] described a patient with vitiligo, poliosis, and unilateral pigmentary retinitis with hyperacusis. During the next 4 years, they observed 2 more patients with similar presentations and were ...

Alezzandrini Syndrome
https://emedicine.medscape.com/article/1117255-print

Jun 8th, 2022 - Practice Essentials In 1959, Casala and Alezzandrini[1] described a patient with vitiligo, poliosis, and unilateral pigmentary retinitis with hyperacusis. During the next 4 years, they observed 2 more patients with similar presentations and were c...

Alezzandrini Syndrome
http://emedicine.medscape.com/article/1117255-overview

Jun 8th, 2022 - Practice Essentials In 1959, Casala and Alezzandrini [1] described a patient with vitiligo, poliosis, and unilateral pigmentary retinitis with hyperacusis. During the next 4 years, they observed 2 more patients with similar presentations and were ...

see more →

Guidelines  1 results

Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents ...
https://doi.org/10.1016/j.ophtha.2013.09.048
Ophthalmology Levy-Clarke G, Jabs DA et. al.

Dec 24th, 2013 - To provide recommendations for the use of anti-tumor necrosis factor α (TNF-α) biologic agents in patients with ocular inflammatory disorders. Ocular inflammatory diseases remain a leading cause of vision loss worldwide. Anti-TNF-α agents are used...

see more →

Drugs  151 results see all →

Clinicaltrials.gov  11 results

Golimumab for the Treatment of Refractory Behcet's Uveitis
https://clinicaltrials.gov/ct2/show/NCT04218565

Apr 26th, 2022 - Uveitis of Behçet's disease (BDU) is the most common form of ocular manifestations, which is also the leading cause of irreversible visual impairment. The aim of the study is to improve the treatment strategy of the disease as well as to reduce bl...

Ustekinumab for Active Sight-Threatening Uveitis
https://clinicaltrials.gov/ct2/show/NCT01647152

Dec 5th, 2019 - Objective: Uveitis refers to intraocular inflammatory diseases that are an important cause of visual loss. Standard systemic immunosuppressive medications for uveitis can cause significant adverse effects and many patients continue to experience d...

Dexamethasone Intravitreal Implant (Ozurdex®) for Recurrent Vogt-Koyanagi-Harada (VKH) Disease Posterior Uveitis
https://clinicaltrials.gov/ct2/show/NCT03971279

Nov 26th, 2019 - Baseline ,and postoperative 1 ,6 ,12 and 24 months full ophthalmic examination was done. Procedure included intravitreal injection of Dexamethasone implant 0.7 mg (Ozurdex(®); Allergan, Inc, Irvine, CA)

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
https://clinicaltrials.gov/ct2/show/NCT04120311

Oct 9th, 2019 - This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from macular edema and other disorders of the retina, choroid and vitreous. Numerous studies have docume...

Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
https://clinicaltrials.gov/ct2/show/NCT01115231

Sep 30th, 2019 - RESEARCH DESIGN AND METHODS A) Study design This study is designed to determine whether smoking increases complement activation and whether there are specific AMD genotypes that are particularly sensitive to this elevated level of serum complement...

see more →

News  27 results

Two uveitis treatment options yield similar success
https://www.mdedge.com/rheumatology/article/207854/ankylosing-spondylitis/two-uveitis-treatment-options-yield-similar
Heidi Splete

Sep 10th, 2019 - Approximately two-thirds of adults with uveitis achieved inflammation control after 6 months on either methotrexate or mycophenolate alongside a reduction in corticosteroid use in an international, multicenter, open-label, randomized trial. “The f.

Behcet's Syndrome: European Treatment Guidelines Updated
https://www.medpagetoday.com/rheumatology/generalrheumatology/72264

Apr 11th, 2018 - Action Points A group of European experts has formulated updated recommendations for the management of Behçet's syndrome, providing up-to-date guidance based on the available literature and expert opinion on potentially controversial topics, such ...

Sustained Drug-Delivery Tech Shows Promise
https://www.medpagetoday.com/ophthalmology/generalophthalmology/69384

Nov 19th, 2017 - Development of technologies for sustained drug delivery is a topic of great interest among retina specialists, considering the number of chronic conditions that are managed with repeated intravitreal injections. Products in this category are alrea...

FDA Clears Adalimumab (Humira) for Uveitis
https://www.staging.medscape.com/viewarticle/865654

Jul 1st, 2016 - The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced. Adalimumab is the first and only FDA-approved nonco...

FDA Clears Adalimumab (Humira) for Uveitis
https://www.medscape.com/viewarticle/865654

Jul 1st, 2016 - The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced. Adalimumab is the first and only FDA-approved nonco...

see more →

Patient Education  1 results see all →